As of August 28, 2026, Virax Biolabs Group Limited (VRAX) has a DilutionWatch DilutionScore of 40/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Virax Biolabs Group Limited has a market capitalization of $1.40M, 579.2K shares outstanding, 6 institutional holders tracked.
This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.
Score Breakdown
📊Float Risk—
Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
model est. 27%
🔄 Reverse Split
model est. 55%
• 50-day avg $0.17 below $1 exchange minimum
Market Data
Market Cap$1.40M
Shares Outstanding579.2K
FloatN/A
Cash$3.44M
Debt$538.0K
Short InterestN/A
Institutional Holdings
6 institutional holders · 35.0K shares
#1
Xtx Topco Ltd
21.4K shares
#2
UBS Group AG
7.5K shares
#3
National Bank of Canada/FI/
6.0K shares
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Short Interest31.5K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jul 31, 2026
Recent SEC Activity
No recent SEC insights
Recent News
No recent news
Track VRAX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking VRAX — Free
Real-time SEC alerts
DilutionScore™ tracking
No credit card required
Score Coverage Note
- Float Risk is excluded because public-float data is unavailable.
More Research for VRAX
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.